Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
Journal of Clinical Oncology · 10.03.2025 · 43 (8) · 912-918
DOI: 10.1200/jco.24.00921 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2025. Verfasst von Shernan G Holtan und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: Cyclophosphamide, Patient Reported Outcome Measures, Graft vs Host Disease, Quality of Life. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS) compared with Tac/methotrexate (MTX) prophylaxis. This companion study assesses the effect of these regimens on patient-reported outcomes (PROs). Using the Lee Chronic GVHD Symptom Score and PROMIS subscales (physical function, GI symptoms, social role satisfaction) as primary end points and hemorrhagic cystitis symptoms and Lee subscales as secondary end points, responses from English and Spanish speakers were analyzed at baseline and days 100, 180, and 365 after transplant. PRO scores were compared between the arms using inverse probability weighted-independent estimating equation models. The PTCy arm had significantly lower scores on the Lee Chronic GVHD Symptom Scale ( P = .01), indicating lower GVHD symptom burden. Lee Scale nutrition and mouth subscores were also better in the PTCy arm compared with the Tac/MTX arm ( P < .01 for both). Older participants (age >65 years) reported better Lee Scale psychological subscores than younger participants ( P = .003). No significant differences were identified in hemorrhagic cystitis or in the PROMIS subscales between treatment arms. The updated clinical end points at 2 years for the parent trial confirmed that PTCy/Tac/MMF maintained a significant advantage over Tac/MTX in GRFS (42.4% v 28.8%, P = .001). In addition to improved GRFS, patients randomly assigned to the PTCy arm reported lower symptom burden during the first year after transplant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
- Bone Marrow Transplantation, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
- The Emmes Company, Rockville, MD.
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University, Nashville, TN.
- Blood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, NY.
ORCID-Profile: Shernan G Holtan, Monzr M Al Malki, Carrie L Kitko, Brian C Shaffer, Melhem M Solh, Karilyn T Larkin, Alison W Loren, Aric C Hall, Omer Jamy, Ami S Bhatt, Miguel-Angel Perales, Mary M Horowitz, Wael Saber, Mehdi Hamadani, Michael J Martens
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
Zitieren
APA
Holtan, S. G., Bolaños-Meade, J., Al Malki, M. M., Wu, J., Kitko, C. L., Reshef, R., Rezvani, A. R., Shaffer, B. C., Solh, M. M., Yao, J. M., Runaas, L., Elmariah, H., Larkin, K. T., El Jurdi, N., Gooptu, M., Loren, A. W., Hall, A. C., Alousi, A. M., Jamy, O., …, & Martens, M. J. (2025). Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. Journal of Clinical Oncology, 43(8), 912-918. https://doi.org/10.1200/jco.24.00921
Vancouver
Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, et al. Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. Journal of Clinical Oncology. 2025;43(8):912-918. doi:10.1200/jco.24.00921
BibTeX
@article{Holtan2025,
author = {Holtan, Shernan G and Bolaños-Meade, Javier and Al Malki, Monzr M and Wu, Juan and Kitko, Carrie L and Reshef, Ran and Rezvani, Andrew R and Shaffer, Brian C and Solh, Melhem M and Yao, Janny M and Runaas, Lyndsey and Elmariah, Hany and Larkin, Karilyn T and El Jurdi, Najla and Gooptu, Mahasweta and Loren, Alison W and Hall, Aric C and Alousi, Amin M and Jamy, Omer and Clark, William and Kean, Leslie and Bhatt, Ami S and Perales, Miguel-Angel and Applegate, Kristy and Efebera, Yvonne Adeduni and Leifer, Eric and Jones, Richard J and Horowitz, Mary M and Mattila, Deborah and Saber, Wael and Hamadani, Mehdi and Martens, Michael J},
title = {Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {8},
pages = {912--918},
doi = {10.1200/jco.24.00921}
}
EUVIMED